AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best stocks under $5 with huge upside potential. Guggenheim lifted the price ...

AtaiBeckley Inc ATAI shares are trading sharply higher on Monday as psychedelic‑related biotech names extend their rally ...

Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on ...

View AtaiBeckley Inc. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN.

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer ...

Enveric Biosciences (ENVB) stock exploded 160%+ after Trump's executive order to accelerate psychedelic drug reviews and $50M ...

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best multibagger penny stocks to invest in. On March 27, Deutsche Bank initiated coverage of AtaiBeckley Inc. (NASDAQ:ATAI) with a Buy rating and a $12 ...

Shares in key competitors COMPASS Pathways and MindMed have shown signs of recovery but Atai shares have remained unchanged. Major news items, such as FDA approval for MDMA-Assisted therapy and phase ...

atai's mission is to tackle the significant unmet needs and lack of innovation in the treatment landscape by working with psychedelic and non-psychedelic compounds. atai is one of the leading ...

Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel ...

In its 2022 Q4 report, Atai reiterated that it is well capitalized, with a cash runway into the first half of 2026. Its sound financial position and deep clinical pipeline appear to have sparked a ...